Physician

Carol R Rapson, MD

According to 2025 Medicare claims, Carol Rapson, MD (NPI: 1073513917) practices medical oncology in the Lansing-East Lansing, MI market, with the plurality of this provider's patient population coming from Ingham, MI. This provider's primary affiliated billing organization is CANCER & HEMATOLOGY CENTERS OF WESTERN MI, P.C. (NPI: 1528018389; TIN: 382777354) and primary practice location at 48823-8053. Rapson is affiliated with the POM ACO (ACO ID: A1297) and Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Rapson's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 259 traditional Medicare patients, billed 60,427 HCPCS/CPT codes, and received $1,527,944 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,289 prescription claims across 279 beneficiaries totaling $4,602,932 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 17 claims. Open Payments data shows 60 records totaling $1,228. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a higher plateau to a lower plateau, from $1,729,037 to $1,527,944. In contrast, Part D prescription costs have moved sharply higher in recent years, from $1,711,497 to $4,602,932. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $3,949 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	650	64,943	$1,729,037
2016	636	37,937	$1,388,366
2017	565	37,806	$1,169,752
2018	583	62,523	$1,761,144
2019	537	60,893	$1,873,285
2020	333	38,994	$1,028,504
2021	290	38,633	$516,229
2022	286	39,620	$879,231
2023	272	35,210	$980,469
2024	259	60,427	$1,527,944

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	346	2,316	$1,711,497
2016	319	2,031	$2,043,272
2017	300	1,664	$2,166,074
2018	298	1,626	$2,542,085
2019	288	1,533	$2,268,235
2020	247	1,287	$2,012,534
2021	288	1,369	$3,227,019
2022	276	1,237	$3,539,607
2023	258	1,229	$3,910,162
2024	279	1,289	$4,602,932

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	34	86	$17,208
2016	45	129	$22,224
2017	18	28	$1,852
2018	41	112	$15,608
2019	18	65	$7,413
2020	N/R	44	$5,960
2021	N/R	14	$1,158
2022	N/R	11	$990
2023	12	28	$2,018
2024	11	17	$1,255

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	121	198	$82
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	138	173	$59
80053	Blood test, comprehensive group of blood chemicals	81	261	$10
36415	Insertion of needle into vein for collection of blood sample	87	228	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	92	331	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	69	1,990	$1,123,858
Revlimid	Lenalidomide	30	840	$737,212
Xtandi	Enzalutamide	39	1,170	$525,947
Verzenio	Abemaciclib	24	728	$391,607
Calquence	Acalabrutinib Maleate	26	770	$367,300

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	11	17	$1,255

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	60	$1,228	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Carol R. Rapson, MD?

Tedicare shows public-source Medicare data for Carol R. Rapson, MD (NPI 1073513917), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Carol R. Rapson, MD have ACO affiliation data?

Carol R. Rapson, MD is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297) and Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Carol R. Rapson, MD?

Carol R. Rapson, MD is linked to CANCER & HEMATOLOGY CENTERS OF WESTERN MI, P.C. (billing NPI 1528018389) in the available physician profile data.

Does Carol R. Rapson, MD have Open Payments data?

Carol R. Rapson, MD has 60 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.